Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2012 Dicembre;53(6) > The Journal of Cardiovascular Surgery 2012 Dicembre;53(6):735-46

ULTIMO FASCICOLOTHE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

REVIEWS  


The Journal of Cardiovascular Surgery 2012 Dicembre;53(6):735-46

lingua: Inglese

Restenosis: a challenge for vascular surgeon

Setacci C. 1, Castelli P. 2, Chiesa R. 3, Grego F. 4, Simoni G. A. 5, Stella A. 6, Galzerano G. 1, Sirignano P. 1, De Donato G. 1, Setacci F. 1

1 Vascular and Endovascular Surgery, University of Siena, Siena, Italy;
2 Department of Surgical Sciences, Vascular Surgery, University of Insubria Medical School, Varese, Italy;
3 Vascular Surgery “Vita Salute” University, Scientific Institute San Raffaele, Milan, Italy;
4 Vascular and Endovascular Surgery, University of Padua, Padua, Italy;
5 Villa Sassi Hospital, Genoa, Italy;
6 Vascular Surgery, Alma Mater Studiorum, University of Bologna, Bologna, Italy


PDF  ESTRATTI


From the beginning of the cardiovascular surgery to the endovascular era restenosis represents the main problem of several spreading vascular disciplines. It can be considered as an excessive wound healing reaction of target vessel of revascularization procedures, that leads to a new narrowing of the vascular lumen. Restenosis still represents the main limiting factor of the long-term success of revascularization procedures. Prevention and strict follow-up are well established techniques in order to reduce restenosis rate and clinical impact of this condition. New drugs as cilostazol have been proven beneficial for patients with de novo lesions of peripheral arteries and cilostazol seems to avoid restenosis process in the majority of patients.

inizio pagina